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Abstract:   23 
Antibodies can play a protective but non-essential role in natural chlamydial infections dependent on 24 
antigen specificity and antibody isotype. IgG is the dominant antibody in both male and female 25 
reproductive tract mucosal secretions, and is bi-directionally trafficked across epithelia by the 26 
neonatal Fc receptor (FcRn). Using physiologically relevant pH-polarized epididymal epithelia grown 27 
on Transwells®, IgG specifically targeting an extracellular chlamydial antigen; the Major Outer 28 
Membrane Protein (MOMP), enhanced uptake and translocation of infection at pH 6-6.5 but not at 29 
neutral pH. This was dependent on FcRn expression. Conversely, FcRn-mediated transport of IgG 30 
targeting the intracellular chlamydial inclusion membrane protein A (IncA), induced aberrant inclusion 31 
morphology, recruited autophagic proteins independent of lysosomes, and significantly reduced 32 
infection. Challenge of female mice with MOMP-specific IgG-opsonized C. muridarum delayed 33 
infection clearance but exacerbated oviduct occlusion. In male mice, MOMP-IgG elicited by 34 
immunization afforded no protection against testicular chlamydial infection, whereas; the transcytosis 35 
of IncA-IgG significantly reduced testicular chlamydial burden. Together these data show that the 36 
protective and pathological effects of IgG are dependent on FcRn-mediated transport as well as the 37 
specificity of IgG for intracellular or extracellular antigens. 38 
 39 
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Introduction: 44 
Chlamydia trachomatis genital infections affect an estimated 90 million people annually 1. Infections 45 
are often asymptomatic (30-50% males, 70-90% females 2), leading to undiagnosed and untreated 46 
epidemics.  In females, C. trachomatis commonly infects the endocervix, leading to an ascending 47 
infection that can cause pelvic inflammatory disease (PID) in an estimated 30% of patients, with 10-48 
20% of PID patients progressing to tubal infertility 3. Similarly in males, chlamydial infection of the 49 
penile urethra can ascend to colonize the prostate, epididymes and testes leading to inflammation, 50 
pathology and potentially infertility 4. CD4+ T helper (Th) 1 cells secreting interferon gamma (IFNγ) 51 
and tumor necrosis factor alpha (TNFα) are known to be crucial in clearance of chlamydial infection 5, 52 
yet this phenotype of T cells are known to breakdown immune privilege in the testes, leading to 53 
autoimmunity against sperm resulting in infertility 6. Thus, the conventional approach to vaccine 54 
development in females (inducing potent Th1 responses) may promote infertility in males, making 55 
antibodies an attractive alternative. As a widely used model of human C. trachomatis infections, 56 
vaginal or penile infection of mice with C. muridarum, leads to an ascending infection and upper 57 
reproductive tract sequelae 7 that closely mimics the human immunopathology 8.  58 
C. trachomatis is an obligate intracellular bacterium with a biphasic life cycle consisting of an 59 
extracellular elementary body (EB) phase, and an intracellular replicative reticulate body (RB) phase. 60 
The EB is resistant to environmental and physical disruptions despite having no detectable 61 
peptidoglycan, but is stabilized with highly cross-linked disulfide-bonded proteins in the outer 62 
membrane (primarily MOMP) 9. Following attachment and infection of the host cell, the EB 63 
differentiates into a RB within a non-fusogenic parasitophorous vacuole termed an inclusion, which is 64 
made up of at least 22 inclusion membrane proteins (e.g. IncA) 10. Within the inclusion, RBs acquire 65 
host nutrients and replicate whilst also secreting proteases (e.g. CPAF) into the host cell cytosol. After 66 
72 hours of infection most RBs have differentiated back into the EB phase and are then released from 67 
the cell by extrusion or lysis allowing further infection. In the context of a vaccine, temporal expression 68 
of chlamydial antigens across the spectrum of the life cycle offer the potential the prevent host cell 69 
attachment, and arrest intracellular replication.  70 
Antibodies are arguably the first line of defense against infection and are responsible for the sterilizing 71 
immunity elicited by the most successful vaccines. However, the role of antibodies in urogenital 72 
chlamydial infections remains controversial. Whilst IgG and Fc gamma receptors (FcγR) appear to 73 
play a pivotal role in acquired immunity against Chlamydia 11-13, EB opsonization by IgG has also 74 
been shown to enhance chlamydial uptake and infection of cells with mouse IgG2b and mouse FcγRII 75 
14, and also mouse IgG3 and human FcγRIII 15. Thus there appears to be contrasting roles for IgG 76 
targeting extracellular EB antigens (specifically MOMP) in vitro and in vivo. More importantly, the 77 
trafficking of these potential enhancing/neutralizing antibodies has received minimal research interest. 78 
The neonatal Fc receptor (FcRn) is ubiquitously expressed throughout the mucosal tissues of 79 
mammals on antigen presenting cells (APCs), syncytiotrophoblasts, endothelial and epithelial cells 16. 80 
FcRn is a major histocompatibility complex class I (MHC-I)-like IgG transporter that requires 81 
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dimerization with beta-2 microglobulin (β2m) to function 17-18. FcRn reversibly binds IgG between 82 
domains CH2-CH3 under acidic conditions (pH 5-6.5) and releases at neutral pH (pH 7.4) 16. 83 
Therefore, FcRn facilitates bidirectional IgG delivery in and out of the lumen of the male and female 84 
reproductive tracts in a pH-dependent manner 19-20. FcRn can also increase the half-life of bound 85 
ligands (IgG and albumin) in vivo 18, translocate IgG-bound antigen through epithelial cells for delivery 86 
to antigen-presenting cells 21, and intraepithelial IgG can also bind and eliminate internalized virus 22. 87 
As FcRn binds IgG at acidic pH and is expressed by reproductive tract epithelia (vagina, uterus, 88 
epididymes, prostate) all of which have an acidic luminal pH, IgG specific for chlamydial extracellular 89 
antigens may increase infectivity by enhancing the uptake of IgG-opsonized Chlamydia. Conversely, 90 
FcRn bound IgG specific for chlamydial intracellular antigens could potentially target internalized 91 
Chlamydia for degradation. In this study we sought to determine the role of FcRn and IgG targeting 92 
intracellular and extracellular chlamydial antigens on infection outcomes at an acidic pH similar to that 93 
of both the male and female reproductive tracts.94 
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Results: 95 
Characterization and Silencing of FcRn in mECap18 Cells. 96 
The mECap18 cells seeded on Transwell® inserts were found to have low TEERs, but were able to 97 
prevent passive flux of 4 kDa FITC dextran by 95% after 5 days and 98% by day 7 (Figure 1B). To 98 
confirm epithelial tight junction formation, cells grown on Transwells® for 5 days were probed for ZO-1 99 
expression (Figure 1C). After 5 days, mECap18 cells had visible ZO-1 protein expression at cell-cell 100 
barriers. Untreated mECap18 cells were found to constitutively transcribe both FcRn (4.5 x 10-2 101 
relative copies to β2m) and FcγRII (4.4 x 10-4 relative copies to β2m) with no detectable FcγRI or 102 
FcγRIII mRNA by qRT-PCR (not shown). Protein expression of FcγRII and FcRn was confirmed by 103 
western blot (Figure 1D). Following transfection with shRNA targeting FcRn mRNA, mECap18 cells 104 
were found to down regulate FcRn mRNA transcription by PCR (Figure 1E), and FcRn protein 105 
expression by western blot (Figure 1D). Silencing of FcRn expression caused a significant 72% 106 
decrease in IgG transcytosis (P < 0.05) (Figure 1F).  107 
FcRn-mediated Uptake and Translocation of IgG-Opsonized Chlamydia 108 
To determine if polyclonal anti-MOMP IgG neutralized or enhanced infection under polarizing 109 
conditions, mECap18 cells (+/- shRNA FcRn) were grown on Transwell® inserts for 5 days, and then 110 
apically infected with EBs opsonized with increasing concentrations of MOMP-IgG. The pH of the 111 
apical medium was adjusted to 6.5 to replicate in vivo epididymal lumen conditions 23. Non-silenced 112 
cells were also treated with wortmannin to chemically inhibit FcγRII/FcRn-mediated enhancement of 113 
infection 14,24. There was an IgG dose-dependent enhancement of infection of MOMP-IgG opsonized 114 
EBs (MOMP-IgG:EBs) (P < 0.01) (Figure 2). EBs treated with 1 g/mL of polyclonal MOMP IgG 115 
demonstrated a 50% enhancement of infection (P < 0.001), and EBs opsonized with 100 µg/mL 116 
enhanced infection by 74% (P < 0.01). This enhancement of infection was abrogated in shRNA-117 
transfected or wortmannin-treated mECap18 cells. The purified MOMP-IgG contained antigen-specific 118 
IgG of all subclasses with the majority of the EB-binding activity seen in IgG1 and IgG2b subclasses 119 
(Supplementary Figure 1).  120 
Translocation of IgG-Opsonized Chlamydial EBs   121 
Having shown that MOMP-IgG enhanced infection of pH-polarized epithelial cells, and transcytosis of 122 
IgG:OVA immune complexes (IC) across epithelia has previously been demonstrated 21, we sought to 123 
determine if epithelial cells could traffic IgG:EB IC from the apical to the basolateral chamber where 124 
they could infect other cells. As chlamydial EBs are approximately 0.31-0.44 µm in size 25, we seeded 125 
mECap18 cells onto 3.0 m inserts. Infection of mECap18 cells grown on the insert membrane was 126 
enhanced by IgG-opsonization of EBs by 77% at pH 6, increasing to 167% (P < 0.01) when FcγRII 127 
was blocked with 2.4G2 (Figure 3A). When observing basolateral infection, a significant increase in 128 
infection (106%, P < 0.01) was observed only in basolateral wells with apical inserts infected at pH 6, 129 
but not blocked with 2.4G2. Similar results were observed when seeding murine macrophage cells 130 
(RAW 264.7) in the basolateral chamber (not shown). Taken together, these data suggest IgG (IgG1 131 
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or IgG2b) targeting extracellularly-exposed domains of the chlamydial EB can enhance binding and 132 
uptake of infectious particles by FcγRII and FcRn. When both receptors are chemically inhibited with 133 
wortmannin or FcRn expression alone was silenced the enhancement of infection was abrogated, yet 134 
when FcγRII was blocked the translocation of opsonized EBs was significantly reduced suggesting 135 
FcγRII may load FcRn with IgG:IC and direct it for basolateral trafficking.. 136 
FcRn Internalized IgG can bind and Neutralize Intracellular Chlamydia 137 
Following infection of polarized mECap18 cells, polyclonal IgG from mice immunized with IncA, 138 
IncMem, CPAF or OVA was added to both apical and basolateral media and IFU determined after 24 139 
h (Figure 4A). IncA-IgG provided significant partial protection (25 %; P < 0.05), in an FcRn-dependent 140 
manner (P < 0.05). IgG targeting inclusion membrane lysates (IncMem) or secreted protease CPAF 141 
failed to provide significant protection against infection compared to OVA-IgG controls. When 142 
observing chlamydial inclusions by microscopy, both IncA/IncMem IgG treated cells exhibited 143 
aberrant inclusion formation (Figure 4B), consistent with microinjection of polyclonal anti-IncA IgG into 144 
cells 26. We also confirmed that C. muridarum begins expressing detectable IncA at 7-8h post 145 
infection using the mouse IncA IgG and anti mouse-IgG-AlexaFluor568 (not shown). Only internalized 146 
FcRn and inclusion-specific IgG was found to co-localize at the inclusion membrane (Figure 4C). 147 
Interestingly however, infection caused FcRn to be internalized and accumulate at the inclusion 148 
regardless of the addition of IgG. Further investigation found that accumulation occurred between 6-8 149 
h post infection (Supplementary Figure 2A), was Chlamydia-mediated and required an intact 150 
microtubule network (Supplementary Figure 2B). This accumulation was also observed in human 151 
epithelial cells infected with C. trachomatis serovars D and L2 (Supplementary Figure 2C), or C. 152 
pneumoniae AR39 (not shown). FcRn-mediated IncA-IgG neutralization was found to be associated 153 
with accumulation of sequestosomal protein p62 (Figure 4D), and independent of lysosomal activation 154 
(Figure 4E). 155 
Infection of Female mice with IgG-Opsonized EBs Delays Recovery from Infection and 156 
Enhances Pathology       157 
To determine if enhancement or translocation of IgG-opsonized EBs occurred in vivo, female mice 158 
were infected with MOMP IgG:EBs, or OVA-IgG treated EBs. Normal infection of WT and β2m -/- 159 
mice saw a peak of infection at day 6, which had resolved by day 24 (Figure 5A). There were no 160 
significant differences in vaginal shedding in any groups, until late in the infection (day 18) when initial 161 
MOMP-IgG opsonization of EBs extended the duration of infection (83% vs WT OVA-IgG infected; P 162 
< 0.05) (Figure 5B).  Interestingly, WT mice infected with MOMP-IgG:EBs had an 80% increase in 163 
hydrosalpinx incidence (P < 0.05) and severity (P < 0.01) (Figure 5C) despite not expressing FcRn 20, 164 
suggesting FcRn-translocation may exaserbate downstream immunopathological responses. WT 165 
mice infected with MOMP-IgG:EBs also and a two-fold increase in intra-stromal lymphocytes in the 166 
uterine horns (P < 0.001)(Figure 5D) compared to WT uninfected or OVA-IgG/EB infected mice. 167 
There were no significant differences in shedding or pathological outcomes in either group of β2m -/- 168 
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mice, suggesting β2m and its heterodimers (FcRn, MHC-I, CD1) play a minimal role in reducing 169 
infectious burden, but an important role in protection from pathology. 170 
Transcytosis of IgG targeting intracellular, but not extracellular chlamydial antigens enhances 171 
protection in male mice 172 
To determine the role of transcytosed IgG targeting extracellular and intracellular chlamydial antigens 173 
in vivo, WT and β2m -/- male C57BL/6 mice were utilized. Initally, intravenous and intraperitoneal 174 
passive immunization of purified IgG was trialled but only transient concentrations (peak 0.1 µg/mL 6h 175 
post immunization) reached the reproductive tract (not shown). To overcome this, we immunized male 176 
mice as done in the in vitro experiments as this schedule has previously been shown to produce 177 
reproductive tract IgG 27, but also depleted mice of CD4+ T cells to maximize the influence humoral 178 
responses on infection. CD4+ T cells were depleted both prior to challenge to eliminate immunization-179 
acquired CD4+ T cells, and continuously throughout infection to prevent T cell-dependent activation of 180 
infection-specific B cells.  181 
Mice were intrasnasally immunized with MOMP, IncA or OVA, depleted of CD4+ T cells and 182 
urogenitally challenged with C. muridarum (Figure 6A). The inability of β2m -/- mice to transport IgG 183 
into tissues was validated by western blot of testes lysates (Figure 6B). To remove the protective role 184 
of CD4+ T cells in immunity, mice were continuously depleted of CD4+ T cells following immunization, 185 
and throughout urogenital infection with all GK1.5-treated groups having >90% reductions in CD4+ T 186 
cells at sacrifice (Figure 6C). All mice had serum antigen-specific IgA (Supplementary Figure 3) and 187 
IgG (Figure 6D) responses as determined by ELISA, however all β2m -/- had a 1-log reduction in Ag-188 
IgG (P < 0.05) likely due to decreased IgG half-life 16,28. Following 3 weeks of infection, WT mice 189 
immunized with either MOMP or IncA had reductions of testicular chlamydial burden of 13% (P < 190 
0.01) and 33% (P < 0.01) respectively when compared to CD4-depleted OVA controls (Figure 6E). 191 
Immunization of β2m -/- mice with MOMP also provided a significant reduction in burden (38%; P < 192 
0.05) but this was not significantly different from MOMP-immunized WT mice (P > 0.05). Interestingly, 193 
protection afforded from IncA immunization of WT mice was completely absent in β2m -/- (P < 0.001). 194 
As naïve testicular infection of C57BL/6 male mice lasts at least 2 months (Supplementary Figure 4), 195 
and live respiratory infections are cleared within 2 weeks and have been shown to provide protection 196 
against genital challenge in females 29, some mice were also intranasally infected with C. muridarum 197 
prior to CD4-depletion and urogenital challenge. Recovery from respiratory infection as determined by 198 
cachexia was found to be supported by β2m expression (60% increase in recovery time of β2m -/- 199 
mice), but non-essential as all strains had recovered by day 15 (Supplementary Figure 5). Mice that 200 
had received a respiratory infection prior to challenge had no significant protection in the reproductive 201 
tract in the absence of CD4+ T cells; however there was a 30% reduction in burden when comparing 202 
IN-infected to OVA-immunized β2m -/- mice. OVA-immunized, mock CD4-depleted (naïve response) 203 
showed no significant differences to OVA-immunized CD4-depleted mice (CD4-defiencent naïve 204 
response) in either strain. 205 
206 
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Discussion:  207 
Antibody-mediated enhancement of chlamydial infections was first reported with HeLa 229 cells 208 
where a murine IgG3 monoclonal antibody enhanced uptake of EBs, facilitated by human FcγRIII 14-15. 209 
IgG2b-opsonization of EBs also enhanced infection of Chinese hamster ovary (CHO) cells transfected 210 
with mouse FcγRII 14. However, neither HeLa nor CHO cells express human FcRn 20,30, and would 211 
have poor affinity for mouse IgG even if present 20,31-32. Thus, we developed a model to investigate 212 
FcRn-mediated enhancement in mouse epithelial cells expressing FcγRII and FcRn. We report that in 213 
addition to FcγRII-mediated enhancement, IgG-opsonized chlamydiae can utilize FcRn to both gain 214 
entry in apical epithelia negating the neutralizing effects of IgG, but also transcytose across apically 215 
acidified epithelial cells where they can go onto infect pH-neutral basolateral cells (epithelial, 216 
fibroblasts, APCs). These data also suggest that epithelial FcγRII binding of IgG:IC may be priming 217 
FcRn to translocate IgG:IC as opposed to internalizing and in an effort to increase IgG halflife. This 218 
cooperation of FcγRs and FcRn has been shown to be important in neutrophil phagocytosis and cross 219 
presentation in DCs 33-34. Interestingly in female mice, enhancement of infection was not observed in 220 
terms of bacterial shedding in the vagina, but upper reproductive tract pathology was exacerbated in 221 
the uterine horns and oviducts simply by initially opsonizing EBs with MOMP-IgG prior to inoculation. 222 
There was a two-fold increase of lymphocyte infiltrate in WT mice inoculated with MOMP-IgG:EBs 223 
compared to all other groups suggesting functional FcRn may have translocated opsonized-EBs and 224 
exacerbated the immune response. Prior inoculation of WT mice with MOMP-IgG:EBs caused a 225 
significant increase in oviduct occlusion compared to OVA-IgG controls, but both β2m-/- groups had 226 
immunopathology demonstrating the vulnerability of β2m-/- mice to oviduct pathology, and makes 227 
enhancement of pathology due to MOMP-IgG:EBs difficult to interpret in this model. Regardless, the 228 
oviduct pathology was surprising as this tissue does not express FcRn 20, suggesting a downsteam 229 
response of FcRn-translocation may be responsible for enhanced immunopathology. We are currently  230 
investigating whether the enhanced pathology in these mice may have been due to CD8-CD11b+ 231 
dendritic cell uptake of IgG:IC and FcRn-mediated cross presentation to CD8+ T cells 34, which are 232 
implicated in aggravated pathological sequelae during chlamydial infection of female mice 35. Due to 233 
volume and physiological limitations in the male mouse model, we immunized and depleted of CD4+ 234 
T cells to remove the protective effect previously published 36. In male mice immunized with MOMP 235 
and depleted of CD4+ T cells, we saw a small 13% reduction in testicular burden, which was not 236 
dependent on the presence of IgG in the testes as there was no significant difference in the absence 237 
of functional FcRn and IgG. Together, this suggests a limited protective role for IgG targeting 238 
membrane proteins on the EB and that other mechanisms are providing protection in this 239 
environment, likely secretory IgA 27. 240 
Our in vitro Transwell® data suggests translocation of IgG-opsonized EBs to the sub-epithelia may be 241 
driving deleterious immunopathology in vivo. We recently reported similar findings showing enhanced 242 
pathology following infection with EBs pre-incubated with vaginal lavages from MOMP-immunized 243 
mice 37. MOMP is a multipass transmembrane protein that is a potent immunogenic antigen which 244 
induces robust cell-mediated and humoral responses during normal infections of both females and 245 
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males, and is the most widely studied vaccine candidate 38. IgG specificity to specific domains of 246 
MOMP is also clinically used in C. trachomatis infections to differentiate serotypes. Thus, the potential 247 
for MOMP-IgG mediated enhancement of infection is not limited to vaccination, but may also enhance 248 
infection/pathology following repeat infections, or in a primary infection contracted from a MOMP-IgG 249 
seropositive sexual partner. In support of increased risk of transmission, human males have been 250 
shown to have up to 24 fold more IgG in urethral secretions when infected with C. trachomatis 39. To 251 
expand on previous studies indentifying antibodies associated with upper reproductive tract pathology 252 
40, it would be interesting to determine if IgG coating of EBs is a predictor for the outcome of 253 
pathological sequelae in females. 254 
To determine the role IgG/FcRn in vivo, we used WT and β2m -/- mice which lack functional FcRn 17-255 
18. Whilst the β2m-/- mice obviously have a deficit in all MHC class I-like proteins that may impact 256 
infection outcomes, the use of appropriate controls (control antigen, with or without CD4-depletion) 257 
should ameliorate concerns.  258 
Whilst IgG and FcRn were found to enhance infection when targeting the extracellular antigen MOMP, 259 
we report that IgG targeting intracellular chlamydial proteins such as IncA was able to target the 260 
inclusion during FcRn-mediated transcytosis. We found that FcRn is recruited independent of IgG to 261 
the inclusion membrane along microtubules, between 6-8 hrs post infection and remains there for the 262 
rest of the infection. This is likely due to the recruitment of RabGTPases by Chlamydia spp. to the 263 
inclusion membrane 41. Whilst the chlamydial inclusion is traditionally considered non-fusogenic with 264 
the endocytic pathway 42, it obtains nutrients including sphingomyelin via fusion with exocytic 265 
trafficking vesicles, primarily using the host cell Rab4+ and Rab11+ GTPase pathways 41,43-44. 266 
Interestingly, both Rab4+ and Rab11+ are crucial in cellular trafficking of FcRn which may suggest 267 
why FcRn was detectable at the inclusion membrane 45.This Chlamydia-mediated accumulation of 268 
FcRn at the inclusion membrane may reduce the ability of IgG to transcytose and bind intracellular 269 
antigens later in the infection cycle. 270 
Intracellular IgG was found to colocalize with FcRn, which together colocalized in the presence of 271 
IncA and IncMem IgG. We also show that the resulting IgG-bound inclusion exhibited aberrant 272 
morphology consistent with microinjection of anti-IncA IgG into infected cells identifying antigen-273 
specific IgG and FcRn dependent colocalization with the inclusion 26. Thus we confirm that IncA is 274 
cytoplasmic facing and can be bound by intracellular IgG, but also that normal cellular transport 275 
mechanism (ie FcRn) can deliver IgG to the inclusion membrane where it can bind, block and 276 
enhance sequestosomal activity. Scidmore et al. have also reported that inclusion membrane proteins 277 
IncG, IncF and CT299 are cytoplasmic facing and can be bound by intracellular IgG, and that 278 
microinjection of CT229 antibodies into infected cells inhibits chlamydial infection 26,44. These three 279 
inclusion membrane proteins are also all expressed within 2 hours of infection making them much 280 
more potent targets for intracellular IgG targeting as FcRn is not internalized to the inclusion 281 
membrane at this time 44,46. If high titers of anti-CT229 IgG could be achieved by vaccination, this may 282 
provide sterilizing immunity in reproductive tract tissues expressing FcRn.  283 
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Unlike FcRn-mediated clearance of internalized virus by IgG via lysosomal degradation 22, we did not 284 
observe LAMP1 aggregates, but rather observed colocalization of IgG, FcRn and the 285 
apoptosis/ubiquitin proteosome marker p62. This is unsurprising as chlamydiae actively inhibit 286 
lysosomal fusion with the inclusion membrane as part of its normal growth 42, but the addition of IncA-287 
IgG led to an accumulation p62 at the inclusion membrane. Whether or not this was responsible for 288 
the reduction in growth requires further investigation.     289 
Antibodies, and in particular IgG, are the principle reason many commercial vaccines are a success 290 
due to their high affinity for foreign antigens, long-lived production, and both systemic and mucosal 291 
circulation. This makes IgG an interesting target in the development of a chlamydial vaccine, 292 
particularly in a male vaccine. Here we demonstrate that FcRn plays a pivotal role on the outcome of 293 
IgG neutralization or enhancement of chlamydial infections, and more excitingly, that intracellular 294 
chlamydial antigens (inclusion membrane proteins and potentially other inclusion-secreted proteins) 295 
are viable candidates for a sub-unit chlamydial vaccine.   296 
297 
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Methods: 298 
Ethics Statement 299 
All experiments were performed with approval from the university animal ethics committee (UAEC) of 300 
Queensland University of Technology (QUT), (UAEC #0800000824 and #0700000346). 301 
Mice 302 
Adolescent (>6 weeks) male and female C57BL/6 WT, and β2m -/- mice were used in these studies. 303 
Adolescent BALB/c male and female mice were also immunized and/or infected for production of 304 
antigen-specific IgG. WT C57BL/6 and BALB/c mice were purchased from the Animal Resource 305 
Centre (Perth, Australia), and breeding pairs of C57BL/6 β2m -/- mice were generously donated by 306 
Prof. Mark Smyth (Peter MacCallum Cancer Centre, East Melbourne, Australia). Mice were fed ad 307 
libitum with procedures performed under physical containment level 2 (PC2) conditions following 308 
NHMRC guidelines. 309 
Cell lines and culture 310 
C. muridarum (Weiss; ATCC VR-123) were propagated in McCoy B cells (ATCC CRL1696) and 311 
purified on a discontinuous Renografin gradient as described elsewhere 9. The hybridomas 2.4G2 and 312 
GK1.5 were generous gifts from Prof. Graham Le Gros (Mallaghan Institute of Medical Research, 313 
Wellington, New Zealand). The SV40-immortalized murine caput epididymal epithelial (mECap18) 314 
cells were a generous gift from Dr. Petra Sipila (Turku University, Turku, Finland)47, and were 315 
maintained in DMEM, 10% heat-inactivated FCS, 100 µg/mL streptomycin sulfate, 50 µg/mL 316 
gentamycin sulfate, 2 mM L-glutamine and 50 nM dihydrotestosterone as described elsewhere 47. An 317 
FcRn knockdown mECap18 clone was established by stable transfection with a short hairpin RNA 318 
(shRNA) pGIPZ vector targeting FcRn mRNA (Open Biosystems # V2LMM-43474). Positively 319 
transfected cells were selected for with 0.1 µg/mL puromycin. Clones were established by limiting 320 
dilution. Silencing of FcRn was determined by qRT-PCR on cDNA isolated from mECap18 cells, 321 
McCoy cells and splenocytes using PCR conditions of 95oC for 10 min, followed by 35 cycles of 95oC 322 
for 20 s, 65oC for 20 s, and 72oC for 20 s on a Rotorgene thermocycler (Qiagen). Exon-spanning 323 
primers for mouse FcRn (NM_010189) and mouse GAPDH (NM_008084.2) mRNA are listed (Table 324 
1). Western blotting was performing following transfer of cell lysates onto nitrocellulose and blocking 325 
with 5% skim milk PBS for 1 h. Blots were incubated with rabbit anti-mouse FcRn-cytoplasmic domain 326 
(purified from the sera of rabbits immunized with the cytoplasmic domain of murine FcRn), rat anti-327 
mouse CD16/32 (2.4G2) or rabbit anti-β-actin (Abcam) for 1 h at room temp, then washed and probed 328 
with corresponding secondary antibody (goat anti-rabbit IgG-HRP or goat anti-rat IgG heavy chain-329 
HRP (Southern Biotech)) for 1 h. Blots were washed with PBS, treated with ECL (Thermo Fischer), 330 
and visualized with a Universal Hood II (Biorad).  331 
Transwell® Assays 332 
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mECap18 cells (± pGIPZ shRNA FcRn) were seeded at 105 cells/insert onto 6.5 mm, 0.4 µm 333 
polyester Transwell® inserts (BD Bioscience), and grown for 5 days, changing the media every 334 
second day (Figure 1A). The transepithelial electrical resistance (TEER) was measured with an 335 
EVOM electrode (Millipore). Electrical resistance was calculated from the formula: resistance of cells 336 
(ohms.cm2) = (resistance of cells – resistance of insert) x surface area of insert (cm2). Passive flux of 337 
FITC dextran (4 kDa) (FD4) was performed as described elsewhere 48. Zona occludens 1 (ZO-1) was 338 
observed in mECap18 cells grown on Transwell® inserts for 5 days, fixed, blocked and probed with 339 
rabbit anti-ZO1 IgG (Invitrogen) for 1 h, and detected with goat anti-rabbit IgG-Alexa Fluor 488 340 
(Invitrogen). DNA was stained with DAPI (Invitrogen) for 20 mins. Transcytosis of mouse IgG 341 
(polyclonal naïve purified IgG), or chicken IgY (Sigma Aldrich) was determined on day 5 post-seeding 342 
as previously described 49. Briefly, 20 µg of polyclonal IgG or IgY was added to the apical chamber of 343 
pH-polarized mECap18 cells (apical pH 6.5, basolateral pH 7.4) and basolateral transport quantified 344 
after 2 h at 37oC by sandwich ELISA.  345 
Production of Antigen-Specific Polyclonal IgG 346 
Full length recombinant C. muridarum MOMP was a generous gift from Dr. Harlan Caldwell (Rocky 347 
Mountain Labs, Hamilton, MT, USA) and was expressed and purified as previously described 50. 348 
Lyophilized control antigen OVA was purchased (Sigma Aldrich) and resuspended in PBS. Full length 349 
recombinant C. muridarum IncA (NP_296774) and CPAF (NP_296627) were produced by amplifying 350 
full length coding sequences with primers (Table 1) using Pfu polymerase (Promega) and hotstart 351 
PCR conditions of 95oC for 2 min, addition of Pfu polymerase, then 35 cycles of 95oC for 1 min, 60oC 352 
for 1 min, and 74oC for 5 min. Amplicons were purified using Purelink PCR purification columns 353 
(Invitrogen) and restriction digested with BamHI/EcoRI (IncA) or BamHI/KpnI (CPAF) for 1 h at 37oC. 354 
Digested amplicons were ligated using T4 DNA Ligase (Promega) into the N’ terminal his-tag vector 355 
pRSET-A (Invitrogen) previously restriction digested with corresponding restriction enzymes. Vectors 356 
were transformed into BL21 (DE3) pLysS E. coli (Invitrogen), grown to O.D.600nm= 0.4 and induced 357 
with 0.5 µM IPTG for 3 h at 30oC. E.coli was lysed and His-tagged protein purified using Talon affinity 358 
resin (Clontech) as per the manufacturers’ instructions. Proteins were eluted with 150 mM imidazole 359 
and dialysed into PBS and stored at -80oC. Inclusion membrane lysates (IncMem) from McCoy B cells 360 
infected for 24 h with C. muridarum were semi-purified by centrifugation as previously described 51. 361 
Mice were intranasally immunized with 20 µg of antigen, 2.5 µg of cholera toxin (CT) (Sapphire 362 
Bioscience), and 10 µg of CpG-ODN (Sigma Aldrich) on day 0, 7, 14 and 25. Serum was collected on 363 
day 35 and polyclonal IgG purified using Protein G resin (Genscript) as per the manufacturer’s 364 
instructions. Purified IgG was stored in PBS at -80oC until required. 365 
In vitro Enhancement or Neutralization of Infection  366 
In vitro neutralization was determined from the formula: neutralization (%) = 100 – ((IFUs per 367 
well/average IFUs of OVA controls) x 100). Enhancement of infection was determined as negative 368 
neutralization. mECap18 (+/- shRNA FcRn) were grown on Transwell® inserts for 5 days, serum 369 
starved in HBSS pH buffered to 7.4 with 30 mM HEPES (HBSS+7.4) for 1 h at 37oC. Cells were then 370 
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pH-polarized for 30 min at 37oC by incubating cells with HBSS+7.4 in the basolateral chamber, and 371 
HBSS buffered to pH 6.5 with 30 mM MES (HBSS+6.5) in the apical chamber. At this point, some 372 
non-transfected mECap18 cells were incubated for 1 h at 37oC with 150 nM wortmannin (Sigma 373 
Aldrich) to inhibit both FcRn and FcγRII-mediated endocytosis 14,24,52. Purified IgG at various 374 
concentrations were incubated with 5 x 104 IFUs of C. muridarum in HBSS+6.5 for 1 h at 4oC to allow 375 
opsonization. The pH-polarized cells were then apically infected for 4 hrs at 37oC. HBSS media was 376 
then removed, and replaced with growth media for 20 hrs (total 24 hrs infection) before fixation with 377 
methanol, and IFUs enumeration by fluorescence microscopy using sheep anti-Cmu MOMP sera as 378 
previously described 53 For intracellular IgG neutralizations, mECap18 cells (+/- shRNA) were grown 379 
for 5 days and then infected with 105 IFUs at 37oC for 1 h. Fresh media (apical pH 6.5, basolateral pH 380 
7.4) containing 100 µg/mL purified mouse IgG (IncA, IncMem, CPAF or OVA-specific mouse IgG) was 381 
then added. After 24 hrs of infections cells were fixed with methanol and IFUs enumerated as above. 382 
For co-localization experiments, fixed cells were blocked with 5% FCS in PBS for 1h, and probed with 383 
rabbit anti-mouse IgG-AlexaFluor568 (Invitrogen), rabbit anti-mouse FcRn-CT, followed by goat anti-384 
rabbit IgG-AlexaFluor488 (Invitrogen); or rabbit anti-LAMP1 (Abcam), or rabbit anti-SQSTM1(p62) 385 
(Abcam) and detected with goat anti-rabbit IgG-AlexaFluor568 (Invitrogen). Coverslips were then 386 
incubated in DAPI (Invitrogen) for 20 min, and mounted onto glass slides with Prolong Gold 387 
(Invitrogen) overnight. Coverslips were imaged with an SP5 confocal microscope (Leica). 388 
Translocation of Opsonized EBs 389 
As opsonization of EBs with MOMP-IgG enhanced apical infection, we sought to determine if IgG-390 
opsonized EBs (0.3-0.45 µm in size) could also be translocated across the monolayer to the 391 
basolateral chamber. mECap18 cells were seeded onto 3.0 µm Transwell® inserts for 5 days. On day 392 
3, 105 mECap18 cells were also seeded into each basolateral chamber of 24 well Transwell® plates. 393 
On day 5, cells were serum starved and pH-polarized as described above. EBs were incubated with 394 
100 µg IgG/105 EBs in HBSS+6 or HBSS+7.4 for 1 h at 4oC to allow opsonization. Prior to infection, 395 
some inserts were apically treated with 2 µg/mL 2.4G2 in HBSS+7.4 for 30 min at 4oC to allow FcγRII 396 
blocking. Unbound antibody was then washed away with ice-cold HBSS+7.4, and cells re-incubated in 397 
HBSS+6 for 15 min at 37oC. Inserts were then apically infected for 4 h at 37oC with IgG-treated EBs, 398 
in HBSS+7.4, HBSS+6, or HBSS+6/2.4G2 block. HBSS was then discarded, and replaced with 399 
growth media for an additional 20 h at 37oC. Following incubation, cells on the inserts and in the 400 
basolateral chambers were washed, fixed and IFUs quantified by fluorescent microscopy.  401 
Chlamydial Infection of Mice 402 
Male C57BL/6 WT and β2m -/- mice were intranasally immunized with MOMP, IncA, or OVA as 403 
described above. To determine if protective antibodies were produced from a previous infection, some 404 
mice were intranasally infected with 103 IFUs on day 0. On day 33, mice were depleted of CD4+ T 405 
cells by intraperitoneal injection of 0.2 mg GK1.5 antibody. Mice were then continuously depleted 406 
every week with 0.1 mg of GK1.5 until sacrifice. On day 35, male mice were urethrally challenged with 407 
106 IFUs of C. muridarum via the glans penis 27,54. Mice were infected for a further 21 days, before 408 
14 
 
they were euthanized on day 56. Testes were collected and homogenized in sucrose phosphate 409 
glutamate (SPG) with a 220V generator probe (OMNI International, Kennesaw, USA) for 10 s, and 410 
stored at -80oC until IFUs were determined by culture on McCoy cells. Testes of uninfected mice were 411 
also collected, homogenized, and solubilized in RIPA buffer, and Western blotted to determine 412 
endogenous IgA and IgG within the tissue using goat anti-mouse IgA-HRP (alpha heavy chain) 413 
(Southern Biotech) and goat anti-mouse IgG-HRP (gamma heavy chain) (Southern Biotech). 414 
Seven days prior to vaginal inoculation, female WT and β2m -/- mice were subcutaneously injected 415 
with 2.5 mg of depot medroxyprogesterone acetate (Pfizer) to synchronize animals in diestrus and 416 
facilitate chlamydial infection 7. Mice were then infected with MOMP-IgG opsonized, or OVA-IgG 417 
treated EBs (40 µg IgG/5 x 103 IFUs in 10 µL SPG). Infection was monitored every 3 days by vaginal 418 
swabbing until euthanasia. On day 35, mice were euthanized, hydrosalpinx formation in the oviducts 419 
recorded, and tissues fixed in 100 % ethanol and prepared for histochemistry. 420 
Statistical Analysis 421 
Statistical analysis of experiments was performed using Graphpad Prism version 5. Unpaired two-422 
tailed Student’s t tests and one way ANOVA with Tukey’s post hoc tests were performed where 423 
indicated. All mouse work was performed using 5 animals per group which was predicted to give 424 
>80% statistical power for shedding data. Significance was determined as * = P < 0.05, ** = P < 0.01, 425 
*** = P < 0.001. Graphs with error bars represent the mean ± the standard error of the mean (S.E.M). 426 
427 
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Figure Legends 598 
 599 
Figure 1: Characterization and Silencing of FcRn in Epididymal Epithelial Cells 600 
(A) Experimental system used throughout this study. (B) Passive apical to basolateral flux of FITC 601 
dextran (FD4) over 2 hrs, and TEERs over time was determined for mECap18 cells grown on 0.4 µm 602 
Transwell® inserts. (C) Tight junction protein ZO-1 expression by mECap18s grown for 5 days on a 603 
Transwell® inserts was determined by anti-ZO-1 antibody and observed with an SP5 confocal 604 
microscope. (D) mECap18 cells were transfected with a shRNA FcRn mRNA silencing vector and 605 
clones screened by Western blot using anti-FcRn, anti-CD16/32, and β-actin antibodies. (E) 606 
mECap18 cells transfected with non-silencing (Mock), or FcRn silencing shRNA1 (#58263) or 607 
shRNA2 (#43474) were analyzed for transcripts of FcRn and GAPDH mRNA by qRTPCR. Murine 608 
fibroblasts (McCoy B) and female BALB/c splenocytes were used as positive controls. Image shows 609 
agarose electrophoresis following qRT-PCR quantification. (B) Apical to basolateral transcytosis of 610 
murine IgG or chicken IgY was determined by growing mECap18 (+/- shRNA2) for 5 days and adding 611 
antibody apically, and measuring the amount of antibody detected in the basolateral chamber after 2 612 
hrs. Statistical significance determined with Student’s t test (n = 3-5 wells per condition). All results 613 
representative of at least 2 individual experiments. Scale bar = 10 µm. Error bars indicative of mean ± 614 
S.E.M. 615 
Figure 2: FcRn-mediates Enhancement of Infection via Uptake of IgG-Opsonized EBs 616 
mECap18 cells (mock or FcRn shRNA) were grown on 0.4µm Transwell® inserts for 5 days and then 617 
apically infected with media at pH 6.5 containing EBs pre-incubated with varying concentrations of 618 
polyclonal MOMP-IgG. Enhancement of infection was determined by comparison with wells infected 619 
with EBs pre-incubated with 100 µg/mL polyclonal OVA-IgG. IFUs were enumerated by fluorescence 620 
microscopy. Groups run in triplicate insert/wells per group. Results are representative of 5 individual 621 
experiments. Statistics determined with Student’s t test. Error bars indicate mean ± SEM. 622 
 623 
Figure 3: FcRn Transcytosis of IgG Opsonized EBs Facilitates Translocation of Infection  624 
mECap18 cells were grown on 3 µm Transwell® inserts for 5 days and infected with EBs pre-625 
incubated with  polyclonal MOMP or OVA IgG. Cells were apically infected under neutral pH (7.4), or 626 
acidic pH (6) with or without CD32-blocking antibody (2.4G2). (A) IFUs quantified in cells in the apical 627 
epithelia. (B) IFUs quantified in the basolateral epithelia following translocation. IFUs were determined 628 
by fluorescence microscopy. Groups run in triplicate insert/wells per group. Results representative of 629 
3 repeat experiments. Statistics determined with Student’s t test. Error bars indicate mean ± SEM. 630 
Figure 4: FcRn internalized IgG binds chlamydial antigens reducing growth and mediating 631 
sequestasomal activation   632 
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(A) Epididymal cells were grown on Transwells® for 5 days, apically infected with C. muridarum for 3-633 
4 hours, and replaced with fresh apical media (pH 6.5) and basolateral media (pH 7.4) containing 634 
polyclonal IgG (100 µg/mL) purified from IncA, IncMem, CPAF or OVA immunized mice for a further 635 
20 hours. Neutralization was determined relative to the mean OVA-IgG controls.  (B-E) mECap18 636 
cells grown on coverslips overnight, and infected for 24 hours with media containing various antigen-637 
specific IgG fixed and stained for fluorescence microscopy. (B) Aberrant inclusion formation, (C) 638 
colocalization of IgG and FcRn with chlamydia inclusion, (D) sequestosome (p62) and (E) lysosomal 639 
(LAMP1) localization. Results representative of 2-3 individual experiments. White arrows identify 640 
chlamydial inclusions. Statistics determined with Student’s t test. Error bars indicate mean of triplicate 641 
wells ± SEM. 642 
 643 
Figure 5: Infection with MOMP-IgG-Opsonized EBs Attenuates Infection Clearance, and 644 
Enhances pathology in the murine FRT 645 
Wild type and β2m -/- female mice were vaginally inoculated with 5 x 103 IFUs pre-incubated with 646 
MOMP IgG or OVA IgG. (A) Kinetics of vaginal shedding following challenge. (B) Cervicovaginal swab 647 
burden at late in infection (day 18). (C) Oviduct occlusion and dilation (hydrosalpinx) after 35 days of 648 
chlamydial challenge. Asterisks represent significant difference in total oviducts with hydrosalpinx (D). 649 
H&E staining of uterine horns following 35 days of infection. Images are representative of 5 separate 650 
mice. Arrows identify lymphocyte infiltration. Number of lymphocytes per 103 cells was determined by 651 
counting H&E sections. Scale bars = 50 µm. Statistics determined with one way ANOVA with Tukey’s 652 
post hoc test. 653 
Figure 6: Protection Provided from Antigen-Specific IgG Targeting Intracellular Chlamydial 654 
Antigen, but not Extracellular Chlamydial Antigen is Dependent on Functional FcRn 655 
(A) Immunization and challenge schedule. (B) Homogenates of testes from naïve WT and β2m -/- 656 
mice were Western blotted for IgA, IgG and β–actin. (C) Representative FACS blot of CD4+ T cells in 657 
the spleen at euthanasia. (D) Serum antigen-specific IgG endpoint titers of WT and β2m -/- mice 658 
immunized with corresponding antigen at euthanasia were determined by direct ELISA. (E) Viable 659 
chlamydial burden in the testes of immunized WT and β2m -/- mice after 3 weeks of infection was 660 
determined by cell culture and quantified by fluorescent microscopy. OVA-immunized, non-depleted 661 
control mice (OVA+). Statistics determined with Student’s t test (D) and one-way ANOVA with Tukey’s 662 
post hoc (E) (n = 5). Asterisks above graph indicate group is significantly different from OVA-663 
immunized CD4-depleted group of the same strain. Dotted lines identify mean of OVA-immunized 664 
CD4-depleted WT and β2m -/- mice. Error bars indicate mean ± SEM. 665 
 666 
Supplementary Figures 667 
Supplementary information is available at Immunology and Cell Biology’s website. 668 
